Explore
Validate
LearnMA1-27198
antibody from Invitrogen Antibodies
Targeting: LRP1
A2MR, APOER, APR, CD91, IGFBP-3R, IGFBP3R1, LRP, LRP1A
Western blot
Other assayAntibody data
- Antibody Data
- Antigen structure
- References [4]
- Comments [0]
- Validations
- Other assay [2]
Submit
Validation data
Reference
Comment
Report error
- Product number
- MA1-27198 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- LRP1 Monoclonal Antibody (8G1)
- Antibody type
- Monoclonal
- Antigen
- Other
- Description
- Perform Western blot analysis under non-reducing conditions. Store product as a concentrated solution. Centrifuge briefly prior to opening the vial.
- Reactivity
- Human
- Host
- Mouse
- Isotype
- IgG
- Antibody clone number
- 8G1
- Vial size
- 100 µg
- Concentration
- 2.0 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references Givinostat-Liposomes: Anti-Tumor Effect on 2D and 3D Glioblastoma Models and Pharmacokinetics.
Midkine activation of CD8(+) T cells establishes a neuron-immune-cancer axis responsible for low-grade glioma growth.
Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death.
Plasma Low-density Lipoprotein Receptor-related Protein 1 Concentration is not Associated with Human Abdominal Aortic Aneurysm Presence.
Taiarol L, Bigogno C, Sesana S, Kravicz M, Viale F, Pozzi E, Monza L, Carozzi VA, Meregalli C, Valtorta S, Moresco RM, Koch M, Barbugian F, Russo L, Dondio G, Steinkühler C, Re F
Cancers 2022 Jun 16;14(12)
Cancers 2022 Jun 16;14(12)
Midkine activation of CD8(+) T cells establishes a neuron-immune-cancer axis responsible for low-grade glioma growth.
Guo X, Pan Y, Xiong M, Sanapala S, Anastasaki C, Cobb O, Dahiya S, Gutmann DH
Nature communications 2020 May 1;11(1):2177
Nature communications 2020 May 1;11(1):2177
Human CD1c(+) DCs are critical cellular mediators of immune responses induced by immunogenic cell death.
Di Blasio S, Wortel IM, van Bladel DA, de Vries LE, Duiveman-de Boer T, Worah K, de Haas N, Buschow SI, de Vries IJ, Figdor CG, Hato SV
Oncoimmunology 2016 Aug;5(8):e1192739
Oncoimmunology 2016 Aug;5(8):e1192739
Plasma Low-density Lipoprotein Receptor-related Protein 1 Concentration is not Associated with Human Abdominal Aortic Aneurysm Presence.
Moxon JV, Behl-Gilhotra R, Morton SK, Krishna SM, Seto SW, Biros E, Nataatmadja M, West M, Walker PJ, Norman PE, Golledge J
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 2015 Oct;50(4):466-73
European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery 2015 Oct;50(4):466-73
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4. Human DCs take up platinum-treated tumor cells in a CRT-dependent manner. ( A ) Percentage of uptake of 15 uM OXP or CDDP treated-BLM cells by CD1c + DCs. Control or treated tumor cells were co-cultured with DCs in the presence of isotype (white bar), CRT blocking peptide (gray bar) or irrelevant tumor antigen (gp100) peptide (black bar) for 2 h. Extent of uptake was assessed by flow cytometry. Data show means of duplicates of one representative experiment. (B) Representative histograms showing CD91 expression on human monocytes (CD14 + ) and DCs (CD16 + , CD1c + , and pDCs). Isotype (gray filled histogram), anti-CD91 (black thick line). (C) Heatmap of relative mRNA expression levels of genes in human DC subsets. Heatmap shows the normalized expression of genes (Z-scores) in CD16 + , CD1c + , and pDCs. Data are represented from three healthy donors. (D) Representative contour plot of CTRL or CDDP (15 uM, 48 h) treated-BLM cells uptake by CD1c + DCs upon functional blocking of CD91 on DCs. BLM cells and DCs were co-cultured overnight in the presence of isotype control or CD91-blocking antibody. Percentage of phagocytosis was assessed by flow cytometry.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Fig. 3 MDK activates T cells to produce Ccl4 through Lrp1/calcineurin/NFAT1 signaling. a T cells expressed only two (Lrp1 and Lrp6) of the putative MDK receptors [protein-tyrosine phosphatase zeta ( Ptprz1 ), neuroglycan-C ( Cspg5 ), low density-lipoprotein receptor-related protein-1 ( Lrp1 ), low density-lipoprotein receptor-related protein-6 ( Lrp6 ) and anaplastic lymphoma kinase ( Alk )] by quantitative RT-PCR. Normal mouse cortex was used as an internal positive control. b Lrp1 blocking antibodies (30 ug ml -1 ) reduced MDK-induced Ccl4 production in T cells. c The 2041C>T neuron conditioned media (N-CM)-mediated Ccl4 production in T cells was attenuated following exposure to Lrp1 receptor blocking antibodies. d Immunoblotting revealed increased NFAT1 nuclear localization in T cells following MDK treatment. Glyceraldehyde 3-phosphate dehydrogenase (GAPDH) and TATA-binding protein (TBP) served as loading controls for the cytoplasm and nuclear fractions, respectively. e Decreased levels of phosphorylated-NFAT1 (p-NFAT) were observed after MDK stimulation of T cells. Lrp1 blocking antibodies (anti-Lrp1, 30 ug ml -1 ) increased NFAT1 phosphorylation and impaired NFAT1 nuclear localization in MDK-stimulated T cells. f The calcineurin inhibitor FK506 (10 muM) inhibited MDK-induced NFAT1 nuclear localization. g Calcineurin inhibitors, cyclosporin (100 nM) and FK506 (10 muM), inhibited MDK-induced Ccl4 production in T cells. h FK506 (10 muM) reduced 2041C>T neuron conditioned me
